secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001193125-25-142816
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial
--------------------------------------------------------------------------------

- 92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.
- 80% complete remission (84% NPM1-m, 74% KMT2A-r); 71% CR-MRD negativity for NPM1-m.
- Median time to MRD negativity 4.7 weeks (NPM1-m) and 4.4 weeks (KMT2A-r).
- Safety consistent with prior data; no QTc prolongation or additive myelosuppression at 600 mg.
- Phase 3 KOMET-017 studies expected to start in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/0001193125-25-142816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525142816/d939526d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-142816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer